Elanco Animal Health Sued Over Alleged Misleading Claims About New Drug Zenrelia’s Safety and Launch Prospects
San Francisco, Oct. 17, 2024 – A recently filed securities class action lawsuit claims that Elanco Animal Health misled its investors about the regulatory path and safety profile of their new dermatology medication, Zenrelia. The legal action targets both the organization and specific upper-level employees for allegedly providing false or misleading information to investors between November 7, 2023, and June 26, 2024. The lawsuit, registered in the U.S. District Court of Maryland, elaborates that Elanco downplayed the safety concerns associated with Zenrelia, an oral Janus kinase inhibitor. Furthermore, the company was overly optimistic about its … Read more